Since Merck will be involved in the study it will have access to information sooner than any one else. So if the drug shows it is working don’t be surprised by a 10 billion dollar buyout sooner than 2027.
Merck will want to roll out a number of studies to maximize its indications and acquire new patents as Keytruda’s patent expires.
Now seems like the worst time to sell.
Ann: Immutep completes institutional pro-rata offer & placement, page-44
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
-0.010(3.13%) |
Mkt cap ! $450.9M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.8¢ | 31.0¢ | $758.7K | 2.412M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 166349 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 312504 | 6 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |